Evidence Intelligence™
- EvidenceScore™
- 86
- Strong
- ImpactScore™
- 76
- Positive
- ConsistencyScore™
- 92
- consistent
Estudios de apoyo: Basado en 13 estudios
Add to Evidence TrackerResumen de Investigación
Analyzed using Evidence Intelligence™
Semaglutide reduces cardiovascular events and body weight in T2D
Última actualización 12 de julio de 2026
Key finding
Semaglutide reduced major adverse cardiovascular events versus placebo.
This study evaluated the effects of semaglutide on cardiovascular events and body weight in adults with type 2 diabetes, finding significant reductions in several cardiovascular outcomes.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Extended (5–20+ y)
Risk of bias
High Risk
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the effects of semaglutide on cardiovascular events and body weight in adults with type 2 diabetes, finding significant reductions in several cardiovascular outcomes.
Clinical relevance
The findings are clinically significant as they suggest that semaglutide not only aids in weight management but also plays a crucial role in reducing serious cardiovascular risks in adults with type 2 diabetes. This could lead to improved long-term health outcomes and reduced healthcare costs associated with diabetes-related complications.
Keep in mind
The analysis was post hoc, which may introduce bias. Results may not be generalizable to all populations. The sample size for specific outcomes may limit robustness.
Published in
Referencia de la Revista
Publication details and source links for this paper.
Stephen CB, Nicolas B, Søren TH, et al. Semaglutide Reduces Cardiovascular Events and Body Weight in Adults with Type 2 Diabetes: A Post Hoc Analysis. Diabetes Therapy. 2024;16(1):15-28. doi:10.1007/s13300-024-01659-7
Efectos Principales
Semaglutide reduced composite cardiovascular events by 25% (p=0.01).
Semaglutide decreased cardiovascular death by 20% (p=0.02).
Semaglutide led to a 15% reduction in nonfatal myocardial infarction (p=0.03).
Body weight decreased by 1.5% with semaglutide compared to placebo (p=0.01).
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Semaglutide and Body weight, Cardiovascular death, Composite cardiovascular events (CV death, MI, stroke, HF hospitalization), and 3 more.
This study contributes evidence to
Primary intervention
Semaglutide
Primary outcomes
- Body weight
- Cardiovascular death
- Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Primary intervention
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
6
Evidence pairs
6
Relationships
4
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 68
4
Related topics
6
Evidence pairs
1135
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 6 evidence relationships
- Includes primary outcome data
- Linked to 4 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Agrega evidencia relacionada a tu Evidence Tracker
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
GLP-1 Receptor Agonists and HbA1c
Evidencia relacionada
Relación de evidencia
GLP-1 Receptor Agonists and Body Weight
Guardar evidencia
Relación de evidencia
GLP-1 Receptor Agonists and Cardiovascular Outcomes
Guardar evidencia
Core evidence
Study findings
The primary outcomes reported in this study.
Evidence Intelligence™
- EvidenceScore™
- 77
- Strong
- ImpactScore™
- 33
- Slightly Negative
- ConsistencyScore™
- 67
- generally_consistent
Estudios de apoyo: Basado en 3 estudios
Add to Evidence TrackerComposite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Semaglutide → Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Semaglutide → Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Evidence Intelligence™
- EvidenceScore™
- 83
- Strong
- ImpactScore™
- 86
- Very Positive
- ConsistencyScore™
- 71
- generally_consistent
Estudios de apoyo: Basado en 7 estudios
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 88
- Strong
- ImpactScore™
- 87
- Very Positive
- ConsistencyScore™
- 88
- consistent
Estudios de apoyo: Basado en 16 estudios
Add to Evidence TrackerIncidence of myocardial infarction
Semaglutide → Incidence of myocardial infarction
Semaglutide → Incidence of myocardial infarction
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 2 estudios
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Strong
- Score 79 · Based on 4 studies
- ImpactScore™
- 38
- Slightly Negative
- ConsistencyScore™
- 35
- mixed
Estudios de apoyo: Basado en 4 estudios
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
La Evidencia Sugiere
- Semaglutide reduced major cardiovascular events by 25%.
- Cardiovascular death decreased by 20% with semaglutide.
- Body weight reduction of 1.5% was observed in the treatment group.
A quién se aplica
- Adults aged 18 and older with type 2 diabetes.
- Individuals at risk for cardiovascular events.
Tener en Cuenta
- The study's post hoc nature may affect the reliability of findings.
- Results may not apply to younger populations or those with different diabetes types.
- Further studies are needed to confirm long-term effects and safety.
Entre Líneas
- The analysis was post hoc, which may introduce bias.
- Results may not be generalizable to all populations.
- The sample size for specific outcomes may limit robustness.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and HbA1c, GLP-1 Receptor Agonists and Body Weight.
Relaciones de evidencia relacionadas
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
GLP-1 Receptor Agonists → HbA1c
Medications
Evidence Intelligence™
- EvidenceScore™
- 88
- Strong
- ImpactScore™
- 87
- Very Positive
- ConsistencyScore™
- 88
- consistent
Estudios de apoyo: Basado en 16 estudios
View evidenceMedications
GLP-1 Receptor Agonists → Body Weight
Medications
Evidence Intelligence™
- EvidenceScore™
- 86
- Strong
- ImpactScore™
- 76
- Positive
- ConsistencyScore™
- 92
- consistent
Estudios de apoyo: Basado en 13 estudios
View evidenceIncluido en estas colecciones de evidencia
Curated evidence collections and hubs this study is part of.
GLP-1 Receptor Agonists Evidence Hub
All studies on GLP-1 Receptor Agonists
16 studies
intervention_hubContributes to GLP-1 Receptor Agonists evidence base.
HbA1c Evidence Hub
All studies measuring HbA1c
16 studies
outcome_hubMeasures HbA1c as a key outcome.
Body Weight Evidence Hub
All studies measuring Body Weight
13 studies
outcome_hubMeasures Body Weight as a key outcome.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explora más en Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Semaglutide and HbA1c
Intervention: SemaglutideOutcome: HbA1c
16 results
All studies on Semaglutide and Body weight
Intervention: SemaglutideOutcome: Body weight
13 results
All studies on Semaglutide
Intervention: Semaglutide
16 results
All studies measuring HbA1c
Outcome: HbA1c
16 results
All studies measuring Body weight
Outcome: Body weight
13 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Do GLP-1 Receptor Agonists lower HbA1c?
Strong Evidence
GLP-1 Receptor Agonists appear to lower HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 88.2 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 45 supporting studies with consistent results and a positive effect signal.
Do GLP-1 Receptor Agonists affect body weight?
Strong Evidence
GLP-1 Receptor Agonists may affect body weight.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Strong | EvidenceScore™ 85.8 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 43 supporting studies with consistent results and a positive effect signal.
Do GLP-1 Receptor Agonists improve cardiovascular outcomes?
Strong Evidence
GLP-1 Receptor Agonists may improve cardiovascular outcomes.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
EvidenceScore™ Strong | EvidenceScore™ 83.2 | strong positive | ConsistencyScore™ Generally Consistent | 1 study
- 2
Nonfatal stroke
EvidenceScore™ Strong | EvidenceScore™ 79.0 | weak negative | ConsistencyScore™ Mixed | 1 study
- 3
Cardiovascular death
EvidenceScore™ Strong | EvidenceScore™ 77.1 | weak negative | ConsistencyScore™ Generally Consistent | 1 study
Why this answer: This answer is based on 13 supporting studies with consistent results and a positive effect signal.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Semaglutide may reduce cardiovascular events in non-diabetic patients.Oral semaglutide reduces cardiovascular events in type 2 diabetesSemaglutide improves insulin sensitivity in adolescents with obesityHigher semaglutide doses improve glucose control in type 2 diabetesNovel Semaglutide Injection Shows Non-Inferior Glycemic Control
Sin anuncios. Sin rastreo.
Centrada en la evidencia, no en la publicidad.
Segura y privada
Tus datos siempre están protegidos.
Siempre al día
Se agregan nuevos estudios todos los días.